These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106 [TBL] [Abstract][Full Text] [Related]
24. New roles for B cell receptor associated kinases: when the B cell is not the target. Nguyen PH; Niesen E; Hallek M Leukemia; 2019 Mar; 33(3):576-587. PubMed ID: 30700840 [TBL] [Abstract][Full Text] [Related]
25. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib. Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871 [TBL] [Abstract][Full Text] [Related]
26. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337 [TBL] [Abstract][Full Text] [Related]
28. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405 [TBL] [Abstract][Full Text] [Related]
30. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. Guo A; Lu P; Coffey G; Conley P; Pandey A; Wang YL Oncotarget; 2017 Feb; 8(8):12953-12967. PubMed ID: 28088788 [TBL] [Abstract][Full Text] [Related]
31. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Roskoski R Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927 [TBL] [Abstract][Full Text] [Related]
32. Ibrutinib in B lymphoid malignancies. Smith MR Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513 [TBL] [Abstract][Full Text] [Related]
33. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. Spaargaren M; de Rooij MF; Kater AP; Eldering E Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503 [TBL] [Abstract][Full Text] [Related]
34. New Means and Challenges in the Targeting of BTK. Nawaratne V; Sondhi AK; Abdel-Wahab O; Taylor J Clin Cancer Res; 2024 Jun; 30(11):2333-2341. PubMed ID: 38578606 [TBL] [Abstract][Full Text] [Related]
35. Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Norman P Expert Opin Investig Drugs; 2016 Aug; 25(8):891-9. PubMed ID: 27148767 [TBL] [Abstract][Full Text] [Related]
36. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755 [TBL] [Abstract][Full Text] [Related]
37. The effect of Bruton's tyrosine kinase (BTK) inhibitor in the eosinophilic asthma model of mouse. Choi Y; Kim SH; Jun Shin S; Park HS; Seob Shin Y Int Immunopharmacol; 2024 May; 132():111903. PubMed ID: 38579561 [TBL] [Abstract][Full Text] [Related]
38. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition. Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125 [TBL] [Abstract][Full Text] [Related]
39. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Winer ES; Ingham RR; Castillo JJ Expert Opin Investig Drugs; 2012 Mar; 21(3):355-61. PubMed ID: 22300471 [TBL] [Abstract][Full Text] [Related]
40. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Tran PN; O'Brien S Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]